Merck has purchased Inspire Pharmaceuticals for its eye-drugs at a price tag of $430 M. This represents a 26% premium over Inspire's current price. The acquisition is part of Merck's strategy to build a franchise to provide improved treatment options for eye diseases. Merck believe the Inspire acquisition will strengthen its opthlamology business and position it for future growth in the area. See Fierce Biotech.
Posted by Bruce Lehr April 5th 2011.
More commentary on this from Seeking Alpha
http://seekingalpha.com/article/261978-the-incredible-shrinking-eye-care-sector
Posted by: bigredbruce | 04/05/2011 at 04:36 PM